ChemoTech: Latest News: New Website for TSE - A Potential New Paradigm in Cancer Care
We're excited to announce that our newly updated website now offers a clearer, more detailed explanation of our Tumour-Specific Electroporation (TSE) technology. With a fresh, modern design and enhanced content, the site is better than ever at showcasing how TSE works and why we believe it has the potential to redefine cancer care.
What's New with TSE on Our Website?
· Clearer Explanation: Our updated website now provides a more in-depth look at how TSE works to target tumours with incredible precision, using electroporation to deliver therapies directly to cancer cells while minimizing damage to surrounding healthy tissue.
· Why TSE Matters: We've outlined what makes TSE a potential new paradigm in cancer treatment-its ability to enhance therapeutic efficacy, reduce side effects, and offer new possibilities for patients with hard-to-treat cancers.
· Innovative Insights: We've included detailed information on the broad potential of TSE, covering its applications across different cancer types and the exciting future this technology holds.
A New Look and Feel
Along with these exciting updates to our content, our website now features a sleek, modern design that's intuitive and easy to navigate. Whether you're visiting from a desktop or mobile device, you'll enjoy a seamless experience while exploring everything we have to offer.
We invite you to explore the new site, discover how TSE could change the landscape of cancer treatment, and share your thoughts with us. As always, we value your feedback!
Visit us at www.chemotech.se.
Thank you for your continued support.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
As of January 9th, 2025, we have discontinued translating our press releases into Swedish. Certain information will still be published in Swedish due to current regulations.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.